The global Sepsis Diagnostics Market, by Product Type (Blood Culture Media, Assays & Reagents, Instruments, and Software), by Method (Automated Diagnostics and Conventional Diagnostics), by Pathogen (Bacterial Sepsis {Gram-Negative Bacterial Sepsis and Gram-Positive Bacterial Sepsis}, Fungal Sepsis, and Others), by Technology (Microbiology, Molecular Diagnostics, Immunoassays, and Flow Cytometry), by End User (Hospitals, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 841.4 Million in 2023 and is expected to exhibit a CAGR of 9.9% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on adopting Organic growth strategies such as the launch of new products, which will drive the global sepsis diagnostics market. For instance, on July 20, 2023, Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for patients suspected of sepsis, announced the adoption of SeptiCyte Rapid by FirstHealth of the Carolinas, a non-profit health system licensed for four hospitals in Pinehurst, Troy, Rockingham, and Raeford, North Carolina. SeptiCyte Rapid is used by FirstHealth as a tool for differentiating sepsis-positive cases from patients with infection negative systemic inflammation.
Global Sepsis Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
The COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. For instance, according to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 769 million cases and 6.9 million deaths due to the Coronavirus (COVID-19) were reported up untill August 13, 2023, across the globe.
The COVID-19 pandemic is expected to boost market growth of sepsis diagnostics due to the growing number of cases of COVID-19 and need for early detection of sepsis associated with COVID-19 infection. Moreover, according to the Global Sepsis Alliance data for 2020, around 2-5% of patients suffering from severe COVID-19 infection show symptoms of sepsis, such as multi-organ damage, within 8-10 days of hospitalization. Furthermore, according to the Canadian Medical Association data for 2020, sepsis is one of the most common complications associated with COVID-19, and it is estimated that the risk of acquiring COVID-19 associated sepsis is 10.4%. Hence, researchers are carrying out intensive studies to develop efficient molecular diagnostic tools for the detection of sepsis and COVID-19.
Global Sepsis Diagnostics Market : Key Developments
On June 2021, Prenosis Inc., an artificial intelligence company enabling precision medicine in acute care, announced has been granted a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), a U.S. government agency. Prenosis has built a large, rapidly growing dataset and biobank from patients with sepsis and other infections. By leveraging its proprietary dataset and AI/ML techniques, Prenosis is creating precision medicine solutions, starting with a sepsis diagnostic tool. Prenosis' Sepsis ImmunoScore intends to enable true precision medicine for infection in hospitals.
Browse 46 market data tables and 42 figures spread through 280 Pages and in-depth TOC on “Global Sepsis Diagnostics Market”- Forecast to 2030, Global Sepsis Diagnostics Market, by Product Type (Blood Culture Media, Assays & Reagents, Instruments, and Software), by Method (Automated Diagnostics and Conventional Diagnostics), by Pathogen (Bacterial Sepsis {Gram-Negative Bacterial Sepsis and Gram-Positive Bacterial Sepsis}, Fungal Sepsis, and Others), by Technology (Microbiology, Molecular Diagnostics, Immunoassays, and Flow Cytometry), by End User (Hospitals, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/sepsis-diagnostic-market-1166
Key Takeaways of the Global Sepsis Diagnostic Market:
- The global sepsis diagnostics market is expected to exhibit a CAGR of 3% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global sepsis diagnostics market.
- Among Product Type, the instruments segment is expected to hold a dominant position in the global sepsis diagnostics market during the forecast period and this is attributed to the technological advancements for sepsis diagnosis. For instance, in November 2021, PERSOWN, Inc., a medical information technology and diagnostics company, has launched the open platform SMASH-H (Sepsis Monitoring and Alerting System for Hospitals and Homes), powered by healthcare analytics from SAS, in order to address the global burden of sepsis. SMASH-H will help hospitals provide access to a common set of predictive models designed to enhance existing IT platforms, monitoring tools, and diagnostic products.
- Among region, North America is expected to be the dominant region in the global sepsis diagnostics market, owing to the key players focusing on organic strategies to start new product launches. For instance, on April 29, 2020, Inflammatix, a California, U.S based molecular diagnostics company delivering precision medicine at the point of care, announced the publication of a health economic model that shows use of the company’s HostDx Sepsis test in patients suspected of acute respiratory tract infections (ARTI) in emergency departments is cost-effective versus standard-of-care. The study was published in the Journal of Health Economics and Outcomes Research. The model informs hospital clinicians of the potential clinical and economic benefits of widespread adoption of the HostDx Sepsis test.
- Major players operating in the global sepsis diagnostics market are BioMérieux SA, Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics AG, Luminex Corporation, CytoSorbents Corporation, Becton Dickinson Company, Danaher Corporation, Axis-Shield Diagnostics, T2 Biosystems, EKF Diagnostics, Immunexpress Inc., Response Biomedical Corporation, and Bruker Corporation
